Estrategias Combinadas en Inmunoterapia Traslacional
ITC
National Cancer Institute
Rockville, Estados UnidosPublications en collaboration avec des chercheurs de National Cancer Institute (9)
2023
-
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60
2021
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9
2015
-
Consensus nomenclature for CD8+ T cell phenotypes in cancer
OncoImmunology, Vol. 4, Núm. 4
-
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014
Journal of Translational Medicine, Vol. 13, Núm. 1
2014
-
Classification of current anticancer immunotherapies
Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508
-
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
Journal of Translational Medicine, Vol. 12, Núm. 1
2011
-
Defining the critical hurdles in cancer immunotherapy
Journal of Translational Medicine
2002
-
Deregulated expression of the PCPH proto-oncogene in rat mammary tumors induced with 7, 12-dimethylbenz[a]anthracene
Molecular Carcinogenesis, Vol. 33, Núm. 4, pp. 219-227
2001
-
Expression of the protein product of the PCPH proto-oncogene in human tumor cell lines
Radiation Research, Vol. 155, Núm. 1, pp. 181-187